Dr. So’s research interests include: acute coronary syndromes, PCI outcomes, pharmacogenomics, personalized anti-platelet therapy and cardiogenic shock. For over 10 years, Dr. So has been leading a group of basic science and clinical researchers in the RAPID program, studying future strategies for personalized anti-platelet therapy. Dr. So also leads the C3 (Canadian Cardiovascular Collaboratory) Cardiogenic Shock Working group, which has assembled a group of cardiovascular specialists from across Canada to collaborate in several Canadian-based cardiogenic shock studies. As part of the RAPID program, Dr. So presented the RAPID GENE study, a late breaking trial at Transcatheter Cardiovascular Therapeutics (TCT) 2011 and published in the LANCET. He has also presented the RAPID CABG trial as a late breaking trial at the American Heart Association Conference (AHA) in 2021.